clinical trial · NCT05582993
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
Takeda·phase3·recruiting·n = 24
Von Willebrand Disease (VWD)Vonicog AlfaADVATE
brief summary
The main aim of the study is to evaluate the effectiveness of prophylaxis with vonicog alfa (recombinant von Willebrand factor \[rVWF\]) in children. This study will enroll those participants who have been previously treated with VWF product or with a plasma-derived VWF (pdVWF) product. In this study, participants will be treated with vonicog alfa (rVWF) for 12 months. During the study, participants will visit the study clinic 5 times after treatment initiation.
started
Nov 6, 2024
primary completion
Apr 11, 2030
completion
Apr 11, 2030
last updated
Oct 15, 2025
official title
A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol